IDiyas

For the Inventor, By the Inventor

Mystic, CT, United States of America

Dennis J Hoover

USPTO Granted Patents = 18 

Average Co-Inventor Count = 2.4

ph-index = 11

Forward Citations = 371(Granted Patents)


Location History:

  • Ledyard, CT (US) (1986 - 1991)
  • Stonington, CT (US) (1995 - 2005)
  • Mysic, CT (US) (2008)
  • Mystic, CT (US) (2002 - 2010)
  • Elkhart, IN (US) (2023)

Company Filing History:

goldMedal16 out of 4,455 
 
Pfizer Corporation
 patents
silverMedal1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1986-2023

Loading Chart...
18 patents (USPTO):Explore Patents
1. 11766963 - Reconfigurable recreational vehicle (2023-09-26),
2. 7825254 - Heteroaromatic quinoline compounds (2010-11-02),
3. 7429665 - Heteroaromatic quinoline compounds (2008-09-30),
4. 6846820 - Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors (2005-01-25),
5. 6649634 - Substituted N-( indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors (2003-11-18),
6. 6410750 - Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid (2002-06-25),
7. 6297269 - Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors (2001-10-02),
8. 6277877 - Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors (2001-08-21),
9. 6107329 - Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as (2000-08-22),
10. 5952322 - Method of reducing tissue damage associated with non-cardiac ischemia (1999-09-14),
11. 5442044 - Orally active renin inhibitors (1995-08-15),
12. 5034376 - Nor-statine and nor-cyclostatine polypeptides (1991-07-23),
13. 4935405 - Nor-statine and nor-cyclostatine polypeptides (1990-06-19),
14. 4859654 - Homocyclostatine and cyclostatine containing polypeptides as (1989-08-22),
15. 4855303 - Fluorine containing renin inhibitors (1989-08-08),

Title: Dennis J Hoover: Pioneer in Heteroaromatic Compounds

Introduction

Dennis J Hoover, based in Mystic, CT, is an accomplished inventor with a remarkable portfolio of 17 patents. His innovative work primarily focuses on heteroaromatic quinoline compounds that serve significant purposes in the field of pharmaceuticals, particularly in the treatment of central nervous system disorders.

Latest Patents

Hoover's latest patents revolve around the invention of heteroaromatic compounds identified as effective phosphodiesterase (PDE) inhibitors. Specifically, his work emphasizes the selective inhibition of PDE10, a target that holds therapeutic promise. His inventive contributions not only include the compounds themselves but also the intermediates required for their preparation, as well as pharmaceutical compositions that incorporate these compounds for therapeutic use.

Career Highlights

Throughout his career, Hoover has made significant strides in the pharmaceutical industry, notably during his tenure at Pfizer Corporation. His dedication to research and development has led to breakthroughs in understanding and utilizing heteroaromatic compounds, establishing him as a respected figure in the field.

Collaborations

In his journey, Hoover has had the opportunity to collaborate with esteemed colleagues such as William H Martin and Judith L Treadway. These partnerships have played a vital role in the progression of his research and the successful realization of his patented inventions.

Conclusion

Dennis J Hoover’s contributions to the field of pharmaceuticals through his innovative inventions are commendable. His ongoing work in the realm of heteroaromatic quinoline compounds showcases his commitment to advancing medical science and improving treatment options for various disorders. As a prolific inventor, Hoover continues to inspire future generations in the world of innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…